

Can-Fite expands its Namodenoson Distribution Deal with CKD

27 February 2019 | News

This agreement extends Can-Fite and CKD's original distribution deal for Namodenoson in treatment of liver cancer



Can-Fite BioPharma, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases has announced the expansion of its distribution agreement with Chong Kun Dang Pharmaceuticals (CKD) in South Korea, for the indication of non-alcoholic steatohepatitis (NASH).

CKD will receive exclusive rights to distribute Namodenoson for the treatment of NASH in addition to liver cancer in South Korea. CKD has agreed to pay Can-Fite \$1,000,000 upfront upon signing, with up to an additional \$5,000,000 upon achieving certain regulatory and sales milestones. Can-Fite will also be entitled to a transfer price for delivering finished product to CKD.

Dr. Sari Fishman, Can-Fite's Director of Business Development said, "The pressing need for an effective drug in this field, where there is still no drug on the market, in our opinion, makes Namodenoson a strong potential candidate as we look towards Phase II results. We look forward to working with CKD to advance Namodenoson in South Korea."

This agreement with CKD marks Can-Fite's expansion of the original deal for another indication with CKD in South Korea.